Payment overview · 2025
General Payments
$50,717.96
132 reported records · 42 companies
Healthcare provider profile · identity verified
Krish Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · NASHVILLE, TN · NPI 1346484821
Verified facts
What the public records show
CMS Open Payments records show Krish Patel, M.D. received $50,717.96 in general payments during 2025 across 132 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 60 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Calquence, Copiktra.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Calquence by this doctor in 2024.
AstraZeneca UK Limited reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 91 records involving 44 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Calquence by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Brukinsa by this doctor in 2024.
BeiGene USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 2084 records involving 1673 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Brukinsa by this doctor in 2024.
Secura Bio, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported COPIKTRA as an associated drug or biological on 294 records involving 210 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Copiktra by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17,660.52 | 34.8% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $11,701.94 | 23.1% | 12 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $5,046.59 | 9.9% | 6 | 2025 |
| AstraZeneca UK Limited | Unresolved — no canonical attribution shown | $4,100.00 | 8.1% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $3,943.17 | 7.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,661.92 | 3.3% | 3 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $1,305.26 | 2.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,223.03 | 2.4% | 2 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $1,046.51 | 2.1% | 5 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $532.52 | 1.1% | 5 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $490.40 | 1.0% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $371.57 | 0.7% | 3 | 2025 |
| Adaptive Biotechnologies Corporation | Unresolved — no canonical attribution shown | $202.22 | 0.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $154.62 | 0.3% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $136.16 | 0.3% | 7 | 2025 |
| Secura Bio, Inc. | Unresolved — no canonical attribution shown | $128.06 | 0.2% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $118.12 | 0.2% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $87.87 | 0.2% | 3 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $82.01 | 0.2% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.99 | 0.1% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $70.91 | 0.1% | 4 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $58.97 | 0.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $56.11 | 0.1% | 2 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $42.32 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.22 | 0.1% | 2 | 2025 |
| Tempus AI, Inc | Unresolved — no canonical attribution shown | $37.16 | 0.1% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $37.11 | 0.1% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $33.83 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.72 | 0.1% | 2 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $25.48 | 0.1% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $24.51 | 0.1% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $24.16 | 0.1% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $21.13 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.19 | 0.0% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $18.60 | 0.0% | 1 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $18.51 | 0.0% | 1 | 2025 |
| Coherus Oncology, Inc. | Unresolved — no canonical attribution shown | $18.50 | 0.0% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $16.07 | 0.0% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $14.97 | 0.0% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $14.95 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.75 | 0.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.31 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $45,047.15 | 15 |
| Food and Beverage | $4,635.52 | 112 |
| Travel and Lodging | $1,035.29 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited | $14,444.48 | 7 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc., BeiGene USA, Inc. | $3,978.76 | 6 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Eli Lilly and Company, Lilly USA, LLC | $1,328.29 | 4 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $1,173.26 | 6 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $265.33 | 3 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $233.23 | 2 | 2025 |
Source payment records
|
|||||
| clonoSEQ Normalized: clonoseq |
Device | Adaptive Biotechnologies Corporation | $202.22 | 2 | 2025 |
Source payment records
|
|||||
| COPIKTRA Normalized: copiktra |
Drug | Secura Bio, Inc. | $128.06 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $124.26 | 5 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $87.87 | 3 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $85.17 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $78.24 | 4 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $78.24 | 4 | 2025 |
Source payment records
|
|||||
| Columvi Normalized: columvi |
Biological | Genentech USA, Inc. | $65.39 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $58.97 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $57.92 | 3 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $56.11 | 2 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $55.08 | 3 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $55.08 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $51.57 | 2 | 2025 |
Source payment records
|
|||||
| Lunsumio Normalized: lunsumio |
Biological | Genentech USA, Inc. | $49.82 | 2 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $49.76 | 2 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $46.42 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $42.32 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $38.22 | 2 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation | $37.51 | 2 | 2025 |
Source payment records
|
|||||
| XT CDX Normalized: xt cdx |
Device | Tempus AI, Inc | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| ABECMA Normalized: abecma |
Biological | Celgene Corporation | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological | Legend Biotech USA Inc. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| ELZONRIS Normalized: elzonris |
Drug | Stemline Therapeutics Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| RETEVMO Normalized: retevmo |
Drug | Lilly USA, LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | ARRAY BIOPHARMA INC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | ARRAY BIOPHARMA INC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| ARROW Normalized: arrow |
Device | Teleflex LLC | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| LOQTORZI Normalized: loqtorzi |
Biological | Coherus Oncology, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 73 | exact normalized | Medicare Part D |
| CALQUENCE calquence |
2025 | Calquence | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| COPIKTRA copiktra |
2025 | Copiktra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| AstraZeneca UK Limited Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 91 supporting records · 44 recipient NPIs · example record 1202913748 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| BeiGene USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 2084 supporting records · 1673 recipient NPIs · example record 1202877750 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| Secura Bio, Inc. Exact reporting entity; no affiliate inference |
2025 | COPIKTRA open payments reported associated product |
CMS Open Payments — General Payments 294 supporting records · 210 recipient NPIs · example record 1193370559 |
Copiktra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 102 | 34 |
| Brukinsa | Zanubrutinib | 73 | 11 |
| Calquence | Acalabrutinib Maleate | 70 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 14 |
| Prednisone | Prednisone | 30 | 12 |
| Entecavir | Entecavir | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Olanzapine | Olanzapine | 20 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | 18 |
| Dexamethasone | Dexamethasone | 19 | suppressed |
| Lenalidomide | Lenalidomide | 15 | suppressed |
| Copiktra | Duvelisib | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50,717.96 · 132 records | E.R. Squibb & Sons, L.L.C. | ABECMA, ADCETRIS, AKEEGA, ARROW, AYVAKIT, BALVERSA, BESREMI, BOSULIF, BRAFTOVI, BREYANZI, BRUKINSA, CABOMETYX, CALQUENCE, CARVYKTI, COPIKTRA, Camcevi, Columvi, ELREXFIO, ELZONRIS, EPKINLY, ERLEADA, Enhertu, GOMEKLI, Itovebi, JAYPIRCA, KEYTRUDA, KISQALI, LIBTAYO, LOQTORZI, LORBRENA, Lunsumio, MEKTOVI, MI CANCER SEEK, MONJUVI, NERLYNX, Nubeqa, OGSIVEO, OJJAARA, OPDIVO, ORGOVYX, Optune Lua (NovoTTF-200T), PADCEV, Polivy, RETEVMO, RYBREVANT, Stivarga, TAGRISSO, TALZENNA, TEVIMBRA, Tecentriq Hybreza, VENCLEXTA, VERZENIO, Vitrakvi, WELIREG, XT CDX, XTANDI, Yescarta, ZEPZELCA, ZYNLONTA, clonoSEQ | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error